ANI Pharmaceuticals (ANIP) Leerink Global Healthcare Conference 2026 summary

Business highlights and growth strategy

• Achieved $883 million in 2025 revenue (44% YoY growth) and $230 million EBITDA (47% YoY growth).

• Rare disease segment, led by Cortrophin Gel, will drive ~60% of 2026 revenues.

• 2026 guidance: $1.055–$1.115 billion revenue (19–26% growth), $275–$290 million EBITDA (20–26% growth).

• Generics business cash flows are reinvested to accelerate rare disease transformation.

• EBITDA margin profile maintained despite $50 million OpEx increase for sales force expansion.

Cortrophin Gel expansion and sales force initiatives

• Cortrophin sales expected to grow from $347 million (2025) to $540–$575 million (2026).

• Growth driven by expanded teams in rheumatology, nephrology, neurology, pulmonology, and ophthalmology.

• New 90-person team (65 sales reps, 8 leaders) targeting acute gouty arthritis flares in primary care and podiatry.

• Pilot programs with PCPs/podiatrists showed strong uptake, informing expansion.

• Full impact of new sales force expected in 2027, with initial effects in Q3/Q4 2026.

Market opportunity and product positioning

• Only ACTH product indicated for acute gouty arthritis flares; competitor lacks this indication.

• Acute gouty arthritis now >15% of Cortrophin volume; pilots identified 7,000 new HCPs to target.

• Addressable U.S. gout market: 9.9 million patients, 285,000 treated with injectables annually.

• Over 50% of current prescribers were previously ACTH-naïve, indicating market expansion.

• Prefilled syringe form now accounts for over 70% of Cortrophin volume, with broad adoption.